Delivery Order SPE2DB24D2010-SPE2DB24FZWH9

Award Date 7/25/24
Potential Completion Date 7/26/24
Potential Value $1.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 150ML, a specialty medication. The award, valued at $2,821.89, is a delivery order under an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which has a total potential value of $999,999,999 and runs through November 2026. The IDC covers a comprehensive...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,040.41 firm fixed price delivery order contract is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 60ML, a specialty medication. The contract has an ultimate completion date of October 30, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,359.98, is for the delivery of QUILLIVANT XR 25 MG/5 ML SUSP 60ML, a pharmaceutical product, with a completion date of December 13, 2023. The contract is a Delivery Order placed under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,850.42 Firm Fixed Price Delivery Order contract is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 120ML, a specialty medication. The contract has an ultimate completion date of October 25, 2024. This appears to be a task order issued under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,855.07, is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 120ML, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of March 24, 2025. This contract award is part of a larger Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $2,582.26, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of QUILLIVANT XR 25 MG/5 ML SUSP 60ML, a pharmaceutical product. The contract has an ultimate completion date of March 14, 2025 and is a Firm Fixed Price Delivery Order. This award is not associated with a set-aside program. AmerisourceBergen Drug Corp holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,834.20 firm fixed-price delivery order is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 150ML, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,747.32 firm fixed-price delivery order is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 120ML, a pharmaceutical product. The contract has an ultimate completion date of November 13, 2024. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,051.36 delivery order covers the supply of QUILLIVANT XR 25 MG/5 ML SUSP 120ML, a pharmaceutical product. The contract has an ultimate completion date of December 17, 2024 and is a firm fixed-price delivery order. There is no set-aside designation for this award. AmerisourceBergen holds a $999,999,999...
This federal contract award, valued at $1,778.42, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4560160111 - QUILLIVANT XR 25 MG/5 ML SUSP 60ML, a medical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has a completion date of March 7, 2023. The contract was not designated with a set-aside requirement, indicating open...
  • SPE2DB24D2010
    Indefinite Delivery Contract
  • SPE2DB24D2010-SPE2DB24FZWH9
    Delivery Order

This federal contract award, valued at $1,315.69, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of QUILLIVANT XR 25 MG/5 ML SUSP 120ML. The contract is a delivery order under an existing Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025. This IDC enables the DLA to efficiently procure a comprehensive range of medical commodities, including prescription drugs and medical supplies, from the vendor to support military treatment programs and facilities worldwide. The award does not have a set-aside designation, and the ultimate completion date is July 26, 2024.

Generated 10/27/24, 3:59 AM